

# CONTAMINATION CONTROL IN HEALTHCARE PRODUCT MANUFACTURING

Volume 5



Russell E. Madsen and Jeanne Moldenhauer  
Editors

[www.pda.org/bookstore](http://www.pda.org/bookstore)

# **Contamination Control in Healthcare Product Manufacturing Volume 5**

**Russell E. Madsen and Jeanne Moldenhauer  
Editors**

To order this book, please visit: [go.pda.org/CCHPM5](http://go.pda.org/CCHPM5)

**PDA  
Bethesda, MD, USA  
DHI Publishing, LLC  
River Grove, IL, USA**

[www.pda.org/bookstore](http://www.pda.org/bookstore)

10 9 8 7 6 5 4 3 2 1

**ISBN: 978-1-942911-28-9**

**Copyright © 2018 Russell E. Madsen and Jeanne Moldenhauer**

**All rights reserved.**

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book. Websites cited are current at the time of publication. The author has made every effort to provide accurate citations. If there are any omissions, please contact the publisher.

While every effort has been made by the publisher and the authors to ensure the accuracy of the information expressed in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the editors and authors and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.



*Connecting People, Science and Regulation®*



This book is printed on sustainable resource paper approved by the Forest Stewardship Council. The printer, Gasch Printing, is a member of the Green Press Initiative and all paper used is from SFI (Sustainable Forest Initiative) certified mills.

**PDA Global Headquarters**

Bethesda Towers, Suite 150  
4350 East-West Highway  
Bethesda, MD 20814  
United States  
[www.pda.org/bookstore](http://www.pda.org/bookstore)  
001-301-986-0293

**Davis Healthcare International Publishing, LLC**

2636 West Street  
River Grove  
IL 60171  
United States  
[www.DHIBooks.com](http://www.DHIBooks.com)

[www.pda.org/bookstore](http://www.pda.org/bookstore)

---

---

# CONTENTS

<b>I</b>	<b>INTRODUCTION</b>	<b>I</b>
	<i>Russell E. Madsen and Jeanne Moldenhauer</i>	
	Background	1
	Types of Contamination	2
	Regulatory Expectations	3
	Contamination Control in the Real World	4
	Materials Provided	5
	References	6
	About the Editors	7

## CONTROL STRATEGIES

<b>2</b>	<b>DEVELOPING A CONTAMINATION CONTROL STRATEGY</b>	<b>II</b>
	<i>Jeanne Moldenhauer</i>	
	Introduction	11
	Purpose of a Contamination Control Strategy	12
	A Comprehensive Written Plan	13
	Design of the Plant and Process	14
	Equipment and Facilities	16

iii

Utilities	20
Raw Materials Control – Including In-Process Controls	21
Product Container and Closures	21
Vendor Approval	22
Outsourced Services	22
Process Risk Assessment	23
Preventative Maintenance	23
Cleaning and Disinfection	23
Monitoring Systems	25
Prevention	25
Trending, Investigations, CAPA and Root Cause Determination	36
Continuous Improvement	36
Conclusion	37
References	38
About the Author	39
<b>3      CASE STUDIES ON TYPICAL MICROBIAL DEVIATIONS THAT CAN BE AVOIDED</b>	<b>41</b>
<i>Walid El Azab and Olivier Chancel</i>	
Introduction	41
The Microbial Control Program and Continuous Improvement	43
Investigation Process and Cross-Functional Team Benefits	45
Microbial Contamination Failures and Lessons Learned	46
Case Study #1: Recurring Microbial Contamination Disrupts The Cost-Time-Quality Balance	47
Case Study #2: Recurring Microbial Contamination in Grade A (ISO 5) Filling Restricted Access Barrier System	61
Case Study #3: Learning Experience on Manual Diaphragm Valves	72
Case Study #4: Learning Experience on Non-Viable Particles, Risks of False Positives	77
Case Study #5: Learning Experience on Moist Heat Sterilization of Filters	84
Case Study #6: Learning Experience on the Risk of False Negatives and Aseptic Process Simulations	88
Case Study #7: Learning Experience on Bioburden, Risks of False and True Positives	90
Conclusion	94
References	94
About the Authors	101

<b>4</b>	<b>FACTORS IN CLEANROOM DECISION MAKING</b>	<b>103</b>
	<i>Sidney Backstrom and Maik Jornitz</i>	
	Introduction	103
	What are the Options?	105
	Decision Factors to Consider	109
	Cost Factors	130
	Quality	132
	Other Factors	136
	Conclusion	138
	References	138
	About the Authors	141
<b>5</b>	<b>DECONTAMINATION OF ITEMS BROUGHT INTO THE CLEANROOM</b>	<b>143</b>
	<i>James Polarine, Jr., Aaron Mertens and Jennifer Loughman</i>	
	Introduction	143
	Cleanroom Design	145
	Cleaning and Disinfection	146
	Contamination Prevention and Control	146
	Selecting a Decontamination Chemistry	148
	Laboratory Studies	149
	Alcohols	149
	Sporicides Comparative Efficacy	152
	Sanitizers, Disinfectants and Sporicides	154
	Equipment Preparation	155
	General Recommendations	156
	References	157
	About the Authors	158
<b>6</b>	<b>THE TECHNOLOGY BEHIND AND SELECTION OF WIPERS FOR USE IN CLEANROOMS</b>	<b>161</b>
	<i>Brad Lyon and Jay Postlewaite</i>	
	Introduction	161
	Yarn	163
	Synthetic Yarns	166
	Fabric Formation Processes	172
	Wiper Uses	193
	Using a Wiper	197
	Cleanroom Wiper Manufacturing	202

Selecting a Wiper	204
Wiper Selection Examples	214
Summary	216
References	216
About the Authors	220

## **7      GAMMA STERILIZATION VALIDATION OF DISPOSABLE, SINGLE-USE AND REUSABLE CLEANROOM GARMENTS      221**

<i>Jan Eudy</i>	
Understanding Cleanroom Apparel Sterilization	221
Steam Autoclaving	223
Ethylene Oxide	223
Ionizing Radiation	224
Design Qualification	225
Installation/Operation Qualification	225
Family Grouping Assessment	227
Sample Item Portion Justification	230
Method I Validation	230
Verification Dose Maximum Method	232
Dose Mapping	235
Performance Qualification	235
Shelf Life Sterilization Stability	236
Routine Monitoring of Gamma Radiation	236
Certificate of Sterility	237
Documentation and Records Retention	238
References	238
About the Author	240

## **ENDOTOXIN RECOVERY**

## **8      ENVIRONMENTAL ENDOTOXINS ARE NON-STATIC STRUCTURES. WHY THE LAL TEST CONTINUES TO BE EFFICACIOUS      243**

<i>John Dubczak and Karen Zink McCullough</i>	
Introduction	243
Purified LPS	245
Size Matters	247
Naturally Occurring Endotoxin: Environment Matters	249

The Dogmatic Analytic Arguments	250
Direct Product Inoculation of an LER Matrix:	
Cell Growth Matters	251
Adaption: Bacterial Physiology and Genetics Matter	254
LPS Structures in Mammalian Cell Culturing Processes	257
Conclusion	260
References	260
About the Authors	262

## ENVIRONMENTAL MONITORING

### 9 PRACTICAL APPROACHES TO LEVERAGING ENVIRONMENTAL MONITORING TREND DATA TO IMPROVE PERFORMANCE 267

*Michael Hodgkinson*

Introduction	267
Background and Regulatory Expectations	268
Program Foundations	270
Environmental Trend Analysis	274
Leveraging Environmental Trend Data to Improve Performance	282
Conclusion	291
References	292
About the Author	293

### 10 DESIGNING A RISK-BASED ENVIRONMENTAL MONITORING PROGRAM FOR NON-STERILE MANUFACTURING 295

*Crystal Booth*

Introduction	295
Overview of Environmental Monitoring	296
Establishing Where to Sample	302
A Phased Approach to EMPQ	305
Routine Environmental Monitoring	307
Establishing Alert Limits	310
Other Considerations	311
Conclusion	312
References	313
About the Author	314



<b>II</b>	<b>AN ENGINEERING PERSPECTIVE ON VALIDATING AN ENVIRONMENTAL MONITORING SAMPLING PLAN</b>	<b>317</b>
	<i>Allan Marinelli</i>	
	Introduction	317
	Sampling Pre-Requisite Phase 1	319
	Sampling Preparation Phase 2	322
	Sampling Execution Phase 3	325
	Sampling to Laboratory Phase 4	335
	Sampling Analysis Phase 5	336
	Sampling Conclusion Phase 6	341
	Conclusion	341
	Appendix Detail Step Section from Sampling Pre-Requisite Phase 1	342
	References	355
	About the Author	356
<b>12</b>	<b>PERSONNEL MONITORING FOR CONTROLLED ENVIRONMENTS</b>	<b>357</b>
	<i>Tim Sandle</i>	
	Introduction	357
	Microbiome of Human Skin and Cleanroom Microbiota	358
	Personnel Gowning and Behavior	372
	Personnel Monitoring	384
	Summary	390
	References	391
	About the Author	397
	<b>OBJECTIONABLE ORGANISMS</b>	
<b>13</b>	<b>CLINICAL RELEVANCE OF OBJECTIONABLE MICROORGANISMS</b>	<b>401</b>
	<i>Ziva Abraham</i>	
	The Challenge	401
	What is Expected?	402
	Knowing the Friendly and Non-Friendly Microbes	405
	Bacterial Pathogens	406
	Fungal Pathogens	408

Infectivity vs. Pathogenicity vs. Virulence	408
Host Susceptibility	409
Infective Dose	409
Objectionable Organisms	409
Specified vs. Objectionable in Oral Dosage Forms	410
Specified vs. Objectionable in Products for Oromucosal and Gingival Use	413
Specified vs. Objectionable in Products for Cutaneous Use and Transdermal Patches	414
Specified vs. Objectionable in Products for Nasal Use	415
Non-invasive Fungal Sinusitis: Mycetoma (Fungus Ball)	416
Invasive Fungal Sinusitis	416
Specified vs. Objectionable in Products for Auricular Use	417
Specified vs. Objectionable in Products for Vaginal Use	418
Specified vs. Objectionable in Inhalation Use (Special Requirements Apply to Liquid Preparations for Nebulization)	418
Specified vs. Objectionable in Eye Products	420
Emerging Infectious Diseases	420
The General Guidance and the Dilemma	421
Research Strategy for Risk Assessment	424
Conclusion	424
References	425
About the Author	431

<b>14</b>	<b>BURKHOLDERIA CEPACIA COMPLEX: SEVERAL ABSOLUTELY-OBJECTIONABLE BACTERIAL SPECIES</b>	<b>433</b>
	<i>Arnaud Carlotti</i>	
	Introduction	433
	Taxonomic Overview	435
	Habitats	443
	Genomic, Infectivity, Virulence and Pathogenicity	446
	Contaminations in the Pharmaceutical Industries	452
	Laboratory Diagnosis	453
	Case Study	455
	Conclusion	461
	References	462
	About the Author	468

<b>I5</b>	<b>BURKHOLDERIA CEPACIA COMPLEX</b>	
	<b>CASE STUDIES</b>	<b>469</b>
	<i>Jeanne Moldenhauer</i>	
	Introduction	469
	BCC Defined	470
	Regulatory Recalls Due to BCC	472
	Case Study 1: Is it BCC?	473
	Case Study 2: Non-Sterile Aqueous Product	476
	Case Study 3: Sterile Aqueous Product	478
	References	482
	About the Author	486
	 <b>APPENDIX</b>	 <b>487</b>
	Contents of Volumes I–4	
	 <b>INDEX</b>	 <b>495</b>